BWAY Quote, Financials, Valuation and Earnings

Can Fite Biofarma has a net margin of 6.3% compared to BrainsWay's net margin of --. BrainsWay's return on equity of 3.54% beat Can Fite Biofarma's return on equity of --.

BrainsWay has a consensus price target of $13.73, signalling upside risk potential of 43.57%. On the other hand Can Fite Biofarma has an analysts' consensus of $14.00 which suggests that it could grow by 700%. Given that Can Fite Biofarma has higher upside potential than BrainsWay, analysts believe Can Fite Biofarma is more attractive than BrainsWay.

BrainsWay has a beta of 1.230, which suggesting that the stock is 22.974% more volatile than S&P 500. In comparison Can Fite Biofarma has a beta of 1.365, suggesting its more volatile than the S&P 500 by 36.503%.

BrainsWay has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can Fite Biofarma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BrainsWay pays -- of its earnings as a dividend. Can Fite Biofarma pays out -- of its earnings as a dividend.

BrainsWay quarterly revenues are $10.5M, which are larger than Can Fite Biofarma quarterly revenues of --. BrainsWay's net income of $662K is higher than Can Fite Biofarma's net income of --. Notably, BrainsWay's price-to-earnings ratio is 101.36x while Can Fite Biofarma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BrainsWay is 4.00x versus 12.73x for Can Fite Biofarma. Usually stocks with elevated PS ratios are considered overvalued.

Compugen has a net margin of 6.3% compared to BrainsWay's net margin of 7.45%. BrainsWay's return on equity of 3.54% beat Compugen's return on equity of 2.69%.

BrainsWay has a consensus price target of $13.73, signalling upside risk potential of 43.57%. On the other hand Compugen has an analysts' consensus of -- which suggests that it could grow by 150%. Given that Compugen has higher upside potential than BrainsWay, analysts believe Compugen is more attractive than BrainsWay.

BrainsWay has a beta of 1.230, which suggesting that the stock is 22.974% more volatile than S&P 500. In comparison Compugen has a beta of 2.588, suggesting its more volatile than the S&P 500 by 158.755%.

BrainsWay has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BrainsWay pays -- of its earnings as a dividend. Compugen pays out -- of its earnings as a dividend.

BrainsWay quarterly revenues are $10.5M, which are smaller than Compugen quarterly revenues of $17.1M. BrainsWay's net income of $662K is lower than Compugen's net income of $1.3M. Notably, BrainsWay's price-to-earnings ratio is 101.36x while Compugen's PE ratio is 53.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BrainsWay is 4.00x versus 2.39x for Compugen. Usually stocks with elevated PS ratios are considered overvalued.

BiomX has a net margin of 6.3% compared to BrainsWay's net margin of --. BrainsWay's return on equity of 3.54% beat BiomX's return on equity of --.

BrainsWay has a consensus price target of $13.73, signalling upside risk potential of 43.57%. On the other hand BiomX has an analysts' consensus of -- which suggests that it could grow by 809.8%. Given that BiomX has higher upside potential than BrainsWay, analysts believe BiomX is more attractive than BrainsWay.

BrainsWay has a beta of 1.230, which suggesting that the stock is 22.974% more volatile than S&P 500. In comparison BiomX has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.797%.

BrainsWay has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BrainsWay pays -- of its earnings as a dividend. BiomX pays out -- of its earnings as a dividend.

BrainsWay quarterly revenues are $10.5M, which are larger than BiomX quarterly revenues of --. BrainsWay's net income of $662K is lower than BiomX's net income of $9.6M. Notably, BrainsWay's price-to-earnings ratio is 101.36x while BiomX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BrainsWay is 4.00x versus -- for BiomX. Usually stocks with elevated PS ratios are considered overvalued.

Pluri has a net margin of 6.3% compared to BrainsWay's net margin of -1804.3%. BrainsWay's return on equity of 3.54% beat Pluri's return on equity of -438.78%.

BrainsWay has a consensus price target of $13.73, signalling upside risk potential of 43.57%. On the other hand Pluri has an analysts' consensus of -- which suggests that it could grow by 583.76%. Given that Pluri has higher upside potential than BrainsWay, analysts believe Pluri is more attractive than BrainsWay.

BrainsWay has a beta of 1.230, which suggesting that the stock is 22.974% more volatile than S&P 500. In comparison Pluri has a beta of 1.664, suggesting its more volatile than the S&P 500 by 66.393%.

BrainsWay has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BrainsWay pays -- of its earnings as a dividend. Pluri pays out -- of its earnings as a dividend.

BrainsWay quarterly revenues are $10.5M, which are larger than Pluri quarterly revenues of $326K. BrainsWay's net income of $662K is higher than Pluri's net income of -$5.9M. Notably, BrainsWay's price-to-earnings ratio is 101.36x while Pluri's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BrainsWay is 4.00x versus 41.58x for Pluri. Usually stocks with elevated PS ratios are considered overvalued.